Lublin

• A study to learn how safe starting vericiguat at a dose of 5 milligrams is in participants with chronic heart failure with reduced ejection … Ended
  2023-507682-25-00 4 2024-05-13 Chronic heart failure with reduced ejection fraction
• A Study to Evaluate the Safety and Effectiveness of ADX-914 in Subjects with Moderate to Severe Atopic Dermatitis Ended
  2023-510238-10-00 4 2024-05-13 Moderate to Severe Atopic Dermatitis
• A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject … Ended
  2023-505842-24-00 5 2024-05-07 Moderate to Severe Plaque Psoriasis
• MYK-224 in Heart Failure with Preserved Ejection Fraction (HFpEF) Ended
  2023-505919-21-00 4 2024-04-25 Heart failure with preserved ejection fraction (HFpEF)
• MLS-101-301: A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of … Ended
  2023-506425-12-00 5 2024-04-17 Uncontrolled and Resistant Hypertension
• A study to assess the efficacy and safety of tigulixostat at different doses as compared to a control drug (allopurinol) in gout patients wi … Ended
  2022-501421-20-00 5 2024-04-09 Gout with hyperuricemia
• A Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia Ended
  2023-506707-25-00 5 2024-04-09 Choroidal neovascularization secondary to pathologic myopia
• A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis Ended
  2023-505841-22-00 5 2024-04-04 Moderate to Severe Plaque Psoriasis
• A phase IIb study to Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Plaque Psoriasis Ended
  2023-506477-35-00 4 2024-04-02 moderate to severe plaque psoriasis
• A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control W … Ended
  2023-507206-13-00 5 2024-03-14 Type 2 Diabetes
• A clinical study of MK-6194 for the treatment of Systemic Lupus Erythematosus (SLE) (MK-6194-006) Ended
  2023-505520-61-00 10 2024-03-11 Systemic Lupus Erythematosus
• A study to evaluate SAR441566 efficacy and safety in adults with rheumatoid arthritis Ended
  2023-503910-60-00 4 2024-03-05 Rheumatoid arthritis
• A Phase 1b Study of Imvotamab in Severe Systemic Lupus Erythematosus Ended
  2023-506499-29-00 3 2024-02-28 Systemic Lupus Erythematosus
• A prospective, randomized, double-blind placebo-controlled multicentre study with mannan-conjugated birch pollen allergoids administered sub … Ended
  2023-508013-16-00 5 2024-02-26 Birch pollen induced allergic rhinitis or rhinoconjunctivitis
• A Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis Ended
  2022-502461-23-00 5 2024-02-15 Prurigo Nodularis
• Dose-response characterization of VER-01 in the treatment of patients with chronic non-specific low back pain Ended
  2023-507358-34-00 4 2024-02-13 For the treatment of patients with chronic non-specific low back pain
• A research study to see how well new weekly medicine IcoSema, which is a combination of insulin icodec and semaglutide, controls blood sugar … Ended
  2022-502484-38-00 5 2024-02-07 Type 2 diabetes
• A study to investigate efficacy and safety of OG-6219 twice a day in 3 dose levels compared with Placebo in participants aged 18 to 49 with … Ended
  2022-501310-57-00 4 2024-02-05 Endometriosis related pain
• A study to test whether BI 456906 helps people living with overweight or obesity who do not have diabetes to lose weight Ended
  2022-502529-17-00 5 2024-01-18 Obesity
• A study to test whether BI 456906 helps people living with overweight or obesity who also have diabetes to lose weight Ended
  2022-502531-18-00 5 2024-01-18 Obesity
• A study evaluating the effects of GLPG3667 given as oral treatment in adults with active systemic lupus erythematosus. Ended
  2023-503183-16-00 4 2024-01-16 Systemic Lupus Erythematosus
• A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 p … Ended
  2023-503333-22-00 5 2024-01-15 Moderate to severe controlled asthma according to Step 4 and Step 5 of
• Hidradenitis Suppurativa Phase 3 Study of Izokibep Ended
  2022-503160-33-00 5 2023-12-15 Hidradenitis Suppurativa
• Extension Study to Assess Batoclimab in Participants with TED. Ended
  2024-512650-21-00 5 2023-12-13 Thyroid Eye Disease (TED)

Showing 625–648 of 786 trials